Evidence map›Paper›PMID 29668739›Full record

ArticlePloS one2018

Physiochemical characterization and cytotoxicity evaluation of mercury-based formulation for the development of anticancer therapeuticals.

N Kannan, S Shanmuga Sundar, S Balaji, Arul Amuthan, N V Anil Kumar, N Balasubramanian

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

N KannanDepartment of Biotechnology, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, India.
S Shanmuga SundarDepartment of Biochemistry and Molecular Biology, University of Debrecen, Debrecen, Hungary.
S BalajiDepartment of Biotechnology, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, India.ORCID 0000-0002-0557-4623
Arul AmuthanDept. of Pharmacology, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.ORCID 0000-0002-6331-1047
N V Anil KumarDepartment of Chemistry, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, India.ORCID 0000-0002-8016-8991
N BalasubramanianDepartment of Chemical Engineering, Anna University, Chennai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe present study is aimed to evaluate the physiochemical properties and cytotoxicity of mercury-based formulation for the development of anticancer therapeuticals.

methodsThe elemental and morphological features of the formulation were characterized by FE-SEM, XPS and EDS. The described formulation was evaluated for its cytotoxicity on Hek293 and MCF7 cell lines using MTT assay to study the in vitro effects. The in vivo developmental toxicity was also studied on zebrafish embryos and the lethal concentration (LC50) values were calculated as per the OECD regulations.

resultsThe elemental and morphological characterizations confirmed the presence of mercuric compounds. The particles were spherical and stable with the size ranges between 20 and 80nm. Although the PK formulation contains mercurials it was very effective only to cancerous cells (MCF-7) and it is less toxic to normal cells (HEK 293). The in vivo assessment of developmental toxicity on zebrafish embryo confirmed the safer dosage of 100μg/ml. However, a higher dosage of 1mg/ml led to the malformation of embryos such as pericardial, tail and yolk sac edema.

conclusionThe physiochemical characterization of PK formulation confirmed the presence of HgS. The results of both in vitro and in vivo studies showed that the formulation is less toxic. Although the test sample contains mercurials it was very effective against cancerous cells (MCF-7) and it is less toxic to normal cells (HEK 293). FUTURE STUDIES: Further studies on effectiveness of the formulation along with inflammatory response in mice models are to be conducted.

Identifiers

PMID29668739
PMCPMC5905971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.